Muneer A. Satter
Founder @ Satter Investment Management
Muneer A. Satter is a Series A investor at Satter Investment Management focused on Health Care and Therapeutics. Muneer Satter manages Satter Investment Management (SIM), a Chicago-based private investment firm, and the Satter Foundation, a private family foundation. SIM has significant investments in several life sciences and medical technology companies.Muneer retired in 2012 after sixteen years as a partner at Goldman Sachs in the Merchant BankingDivision. As Global Head of Goldman Sachs Mezzanine Group, Muneer raised and managed more than $30 billion of investments.He is Vice Chairman of the Board of the Goldman Sachs Foundation and he is on the Board of the Nature Conservancy where he is Chairman of the Finance Committee. Muneer received a B.A. from Northwestern University, and a JD/MBA from Harvard Law School and Harvard Business School. Muneer served on the Room to Read Board of Directors from 2004 to 2010 and was Co-Chair from 2005 to 2008.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Muneer A. Satter invests in
Stages Muneer A. Satter invests in
Countries Muneer A. Satter invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 2 (67%)
- Therapeutics 2 (67%)
- Biotechnology 2 (67%)
- Clinical Trials 1 (33%)
- Health Diagnostics 1 (33%)
Stage
- Series A 1 (33%)
- Series C 1 (33%)
- Series E 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Alzheon is a clinical-stage biotechnology company focused on womanchild brain health, memory, and aging, developing transformative treatments for Alzheimer’s disease and other neurodegenerative disorders. They are building a pipeline of innovative drugs to improve the lives of patients by preventing the cognitive and functional decline associatedwith neurodegeneration.They have a distinct ability to make success advances in the challenging field of therapeutics for Alzheimer’s and other neurodegenerative disorders. | $100M / Series E / Jun 12, 2024 | ||
| Aerpio Pharmaceuticals is a new, clinical-stage biotechnology company focused on the development of novel small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Aerpio was created in a spin-out transaction from Akebia Therapeutics to enable more rapid development of its exciting compounds.It is managed by the same successful team from Akebia, employing a similar outsourced approach to pharmaceutical development.Aerpio Pharmaceuticals was founded in 2011 and is based in Cincinnati, Ohio, United States. | $22M / Series C / Apr 23, 2014 | ||
| Aerpio Pharmaceuticals is a new, clinical-stage biotechnology company focused on the development of novel small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Aerpio was created in a spin-out transaction from Akebia Therapeutics to enable more rapid development of its exciting compounds.It is managed by the same successful team from Akebia, employing a similar outsourced approach to pharmaceutical development.Aerpio Pharmaceuticals was founded in 2011 and is based in Cincinnati, Ohio, United States. | $36M / Series A / Nov 06, 2013 |
Co-Investors
Satter Investment Management is a principal investment firm specializing in investments in life sciences and medical technology companies.
Satter Investment Management Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Muneer A. Satter
Founder
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Muneer A. Satter invest in?
Muneer A. Satter invests primarily in Health Care, Therapeutics and Biotechnology startups, most often at Series A and Series C stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Muneer A. Satter?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Muneer A. Satter last invest?
The most recent investment recorded for Muneer A. Satter closed in Jun 2024. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
